Replimune Group, Inc. (REPL) stock
REPLNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends March 31
Financials through Q2 FY2027, quarter ended Sep 30, 2026Last filing: 10-Q/A on Nov 6, 2026Score 1/30
$21.78−1.50 (-6.44%)
Close on Nov 11, 2026Market cap $2.06BP/E –Yield –
Replimune enterprise value
Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.
Replimune's enterprise value was $1.72B on Nov 11, 2026, against $505.89M a year earlier. Over the last 5 years it ranged from -$78.17M to $1.72B, with a median of $398.81M.
Enterprise Value at the end of each year
| Period | Period end | Value | Change |
|---|---|---|---|
| 2026 | Nov 11, 2026 | $1.72B | +255.0% |
| 2025 | Dec 31, 2025 | $483.94M | +10.0% |
| 2024 | Dec 31, 2024 | $440.07M | – |
| 2023 | Dec 29, 2023 | -$526.74K | -100.1% |
| 2022 | Dec 30, 2022 | $979.46M | +17.7% |
| 2021 | Dec 31, 2021 | $832.37M | -35.6% |
| 2020 | Dec 31, 2020 | $1.29B | +286.8% |
| 2019 | Dec 31, 2019 | $333.95M | +100.6% |
| 2018 | Dec 31, 2018 | $166.46M | – |
See a number that looks wrong?